SEC Info - Revance Therapeutics, Inc. - ‘10-K’ for 12/31/18

SEC Info℠

Home

Help

Please Sign In

Revance Therapeutics, Inc. – ‘10-K’ for 12/31/18 – ‘EX-32.2’

On: Thursday, 2/28/19, at 5:21pm ET · For: 12/31/18 · Accession #: 1479290-19-30 · File #: 1-36297

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/28/19  Revance Therapeutics, Inc.        10-K       12/31/18   86:11M

Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.88M 
 2: EX-10.27    Material Contract                                   HTML     31K 
 3: EX-10.28    Material Contract                                   HTML     26K 
 4: EX-10.37    Material Contract                                   HTML     52K 
 5: EX-10.38    Material Contract                                   HTML     26K 
 6: EX-10.42    Material Contract                                   HTML    297K 
 7: EX-21.1     Subsidiaries List                                   HTML     22K 
 8: EX-23.1     Consent of Experts or Counsel                       HTML     25K 
 9: EX-31.1     Certification -- §302 - SOA'02                      HTML     30K 
10: EX-31.2     Certification -- §302 - SOA'02                      HTML     30K 
11: EX-32.1     Certification -- §906 - SOA'02                      HTML     27K 
12: EX-32.2     Certification -- §906 - SOA'02                      HTML     27K 
19: R1          Document and Entity Information                     HTML     58K 
20: R2          Consolidated Balance Sheets                         HTML    107K 
21: R3          Consolidated Balance Sheets (Parenthetical)         HTML     34K 
22: R4          Consolidated Statements of Operations and           HTML     77K 
                Comprehensive Loss                                               
23: R5          Consolidated Statements of Stockholders Equity      HTML    103K 
24: R6          Consolidated Statements of Stockholders? Equity     HTML     28K 
                (Parenthetical)                                                  
25: R7          Consolidated Statements of Cash Flows               HTML    134K 
26: R8          The Company and Basis of Presentation               HTML     36K 
27: R9          Summary of Significant Accounting Policies          HTML    118K 
28: R10         Revenue                                             HTML     55K 
29: R11         In-Process Research and Development                 HTML     30K 
30: R12         Medicis Settlement                                  HTML     34K 
31: R13         Cash Equivalents and Investments                    HTML     84K 
32: R14         Fair Value Measurements                             HTML     88K 
33: R15         Balance Sheet Components                            HTML     63K 
34: R16         Notes Payable                                       HTML     33K 
35: R17         Commitments and Contingencies                       HTML     46K 
36: R18         Stockholders' Equity                                HTML    349K 
37: R19         Income Taxes                                        HTML    104K 
38: R20         Defined Contribution Plan                           HTML     28K 
39: R21         Subsequent Events                                   HTML     28K 
40: R22         Quarterly Results of Operations (Unaudited)         HTML     66K 
41: R23         Summary of Significant Accounting Policies          HTML    172K 
                (Policies)                                                       
42: R24         Summary of Significant Accounting Policies          HTML     35K 
                (Tables)                                                         
43: R25         Cash Equivalents and Investments (Tables)           HTML     79K 
44: R26         Fair Value Measurements (Tables)                    HTML     87K 
45: R27         Balance Sheet Components (Tables)                   HTML     56K 
46: R28         Commitments and Contingencies (Tables)              HTML     32K 
47: R29         Stockholders' Equity (Tables)                       HTML    326K 
48: R30         Income Taxes (Tables)                               HTML     91K 
49: R31         Quarterly Results of Operations (Unaudited)         HTML     65K 
                (Tables)                                                         
50: R32         The Company and Basis of Presentation - Additional  HTML     53K 
                Information (Detail)                                             
51: R33         Summary of Significant Accounting Policies          HTML    123K 
                (Details)                                                        
52: R34         Summary of Significant Accounting Policies -        HTML     35K 
                Summary of Antidilutive Securities (Details)                     
53: R35         Revenue (Details)                                   HTML     85K 
54: R36         In-Process Research and Development (Details)       HTML     42K 
55: R37         Medicis Settlement - Additional Information         HTML     60K 
                (Detail)                                                         
56: R38         Cash Equivalents and Investments (Details)          HTML     50K 
57: R39         Cash Equivalents and Investments - Additional       HTML     26K 
                Information (Details)                                            
58: R40         Fair Value Measurements - Schedule of Fair Value    HTML     62K 
                of Financial Instruments (Detail)                                
59: R41         Fair Value Measurements - Summary of Changes in     HTML     31K 
                Fair Value of Financial Instruments (Detail)                     
60: R42         Balance Sheet Components - Schedule of Property     HTML     45K 
                and Equipment, Net (Detail)                                      
61: R43         Balance Sheet Components - Additional Information   HTML     45K 
                (Detail)                                                         
62: R44         Balance Sheet Components - Schedule of Accruals     HTML     46K 
                and Other Current Liabilities (Detail)                           
63: R45         Notes Payable - Essex Capital Notes (Detail)        HTML     54K 
64: R46         Commitments and Contingencies - Additional          HTML     58K 
                Information (Detail)                                             
65: R47         Commitments and Contingencies - Schedule of Future  HTML     45K 
                Minimum Lease Payments under Non-Cancelable                      
                Operating Leases (Detail)                                        
66: R48         Stockholders' Equity - Convertible Preferred Stock  HTML     42K 
                (Details)                                                        
67: R49         Stockholders' Equity - Warrants (Details)           HTML     48K 
68: R50         Stockholders' Equity - Stock Option Plan -          HTML    143K 
                Additional Information (Details)                                 
69: R51         Stockholders' Equity - Stock Option Plan - Summary  HTML    118K 
                of Stock Option and Restricted Stock Activity                    
                (Details)                                                        
70: R52         Stockholders' Equity - Stock Option Plan - Stock    HTML     77K 
                Options Outstanding and Exercisable (Details)                    
71: R53         Stockholders' Equity - Stock Option Plan - Summary  HTML     58K 
                of Restricted Stock Activity (Details)                           
72: R54         Stockholders' Equity - Stock Option Plan - Fair     HTML     45K 
                Value Assumptions (Details)                                      
73: R55         Stockholders' Equity - Stock Option Plan -          HTML     33K 
                Schedule of Stock-based Compensation Expense                     
                (Details)                                                        
74: R56         Stockholders' Equity - Common Stock (Details)       HTML     94K 
75: R57         Income Taxes - Components of Net Income (Loss)      HTML     32K 
                (Details)                                                        
76: R58         Income Taxes - Deferred Tax Assets and Liabilities  HTML     44K 
                (Details)                                                        
77: R59         Income Taxes - Additional Information (Detail)      HTML     84K 
78: R60         Income Taxes - Effective Tax Rate Reconciliation    HTML     50K 
                (Details)                                                        
79: R61         Income Taxes - Unrecognized Tax Benefits (Details)  HTML     33K 
80: R62         Defined Contribution Plan - Additional Information  HTML     26K 
                (Details)                                                        
81: R63         Subsequent Events - Additional Information          HTML     33K 
                (Details)                                                        
82: R64         Quarterly Results of Operations (Unaudited) -       HTML     44K 
                Additional Information (Details)                                 
84: XML         IDEA XML File -- Filing Summary                      XML    144K 
18: XML         XBRL Instance -- rvnc1231201810k_htm                 XML   2.67M 
83: EXCEL       IDEA Workbook of Financial Reports                  XLSX    105K 
14: EX-101.CAL  XBRL Calculations -- rvnc-20181231_cal               XML    199K 
15: EX-101.DEF  XBRL Definitions -- rvnc-20181231_def                XML    789K 
16: EX-101.LAB  XBRL Labels -- rvnc-20181231_lab                     XML   1.81M 
17: EX-101.PRE  XBRL Presentations -- rvnc-20181231_pre              XML   1.11M 
13: EX-101.SCH  XBRL Schema -- rvnc-20181231                         XSD    171K 
85: JSON        XBRL Instance as JSON Data -- MetaLinks              366±   578K 
86: ZIP         XBRL Zipped Folder -- 0001479290-19-000030-xbrl      Zip    490K

‘EX-32.2’ — Certification — §906 – SOA’02

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

<! C: C:

Exhibit

Exhibit 32.2

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Tobin C. Schilke, Chief Financial Officer of Revance Therapeutics, Inc. (the “Company”), hereby certifies that, to the best of his knowledge:


1.	The Company’s Annual Report on Form 10-K for the period ended December 31, 2018 (the “Annual Report”), to which this Certification is attached as Exhibit 32.2, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and


2.	The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

In Witness Whereof, the undersigned has set his hand hereto as of the 28^th day of February, 2019.



	/s/ *Tobin C. Schilke*
	Tobin C. Schilke
	Chief Financial Officer

“This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Revance Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.”

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-K’ Filing	Date	Other Filings

Filed on:	2/28/19	S-8
For Period end:	12/31/18	4, DEF 14A
		List all Filings

4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/28/24  Revance Therapeutics, Inc.        10-K       12/31/23  110:12M
 2/28/23  Revance Therapeutics, Inc.        10-K       12/31/22  109:14M
 2/28/22  Revance Therapeutics, Inc.        10-K       12/31/21  106:12M
 2/25/21  Revance Therapeutics, Inc.        10-K       12/31/20  109:12M

↑Top

Filing Submission 0001479290-19-000030 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)